Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis
<h3>Background</h3><p dir="ltr"><u>Primary central nervous system lymphoma</u> (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose <u>methotrexate</u> (HD-MTX), are effe...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513538650800128 |
|---|---|
| author | Jaber H. Jaradat (21632849) |
| author2 | Ibraheem M. Alkhawaldeh (17430888) Yousef Al-Bojoq (22282816) Monther N. Ramadan (22282819) Mohammad T. Abuawwad (17632242) Yasmeen Jamal Alabdallat (19920491) Abdulqadir J. Nashwan (11659453) |
| author2_role | author author author author author author |
| author_facet | Jaber H. Jaradat (21632849) Ibraheem M. Alkhawaldeh (17430888) Yousef Al-Bojoq (22282816) Monther N. Ramadan (22282819) Mohammad T. Abuawwad (17632242) Yasmeen Jamal Alabdallat (19920491) Abdulqadir J. Nashwan (11659453) |
| author_role | author |
| dc.creator.none.fl_str_mv | Jaber H. Jaradat (21632849) Ibraheem M. Alkhawaldeh (17430888) Yousef Al-Bojoq (22282816) Monther N. Ramadan (22282819) Mohammad T. Abuawwad (17632242) Yasmeen Jamal Alabdallat (19920491) Abdulqadir J. Nashwan (11659453) |
| dc.date.none.fl_str_mv | 2024-12-24T18:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.critrevonc.2024.104597 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_ibrutinib_in_central_nervous_system_lymphoma_A_systematic_review_and_meta-analysis/30173485 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Ibrutinib BTK Bruton tyrosine kinase inhibitor CNSL Central nervous system lymphoma Lymphoma |
| dc.title.none.fl_str_mv | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr"><u>Primary central nervous system lymphoma</u> (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose <u>methotrexate</u> (HD-MTX), are effective treatments, the relapse rates remain high, prompting the exploration of novel therapeutic options.<u> Ibrutinib</u>, an irreversible <u>Bruton tyrosine kinase</u> (BTK) inhibitor, has shown promise in various B-cell <u>malignancies</u>, including <u>CNSL.</u></p><h3>Objectives</h3><p dir="ltr">This <u>systematic review </u>and meta-analysis aimed to evaluate the safety and efficacy of ibrutinib in the treatment of CNSL, focusing on <u>overall response</u> (OR), complete response (CR), partial response (PR), progression-free survival (PFS), overall survival (OS), and <u>adverse events.</u></p><h3>Methods</h3><p dir="ltr">A comprehensive search of the <u>PubMed</u>, Google Scholar, and <u>Scopus</u> databases was conducted. The included studies were prospective and retrospective studies focusing on ibrutinib as <u>monotherapy</u> or in combination with CNSL. <u>Data extraction</u> and quality assessment were independently performed by two reviewers, and statistical analyses were conducted using R version 4.4.0.</p><h3>Results</h3><p dir="ltr">Fourteen studies (eight <u>cohort studies </u>and six clinical trials) involving 784 patients were included. The median age was 61 years, with nearly equal sex distribution. The meta-analysis for CNSL, the partial response rate was 29.52 %, complete response rate was 49.19 %, and overall response rate was 72.11 %. For PCNSL, the partial response rate was 20.85 %, complete response rate was 48.13 %, and overall response rate was 66.92 %. For SCNSL, the partial response rate was 29.42 %, complete response rate was 44.64 %, and overall response rate was 66.82 %. Significant heterogeneity was observed in some comparisons. There were no significant differences in the efficacy of ibrutinib between CNSL subtypes.</p><h3>Conclusions</h3><p dir="ltr"><u>Ibrutinib</u> shows promising efficacy in improving partial and complete response rates in CNSL. The substantial heterogeneity observed underscores the need for further well-designed studies to confirm these findings and explore the optimal use of ibrutinib in CNSL treatment protocols. Future trials should consider comparing ibrutinib to standard therapies and investigate its long-term efficacy and safety profile.</p><h2>Other Information</h2><p dir="ltr">Published in: Critical Reviews in Oncology/Hematology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.critrevonc.2024.104597" target="_blank">https://dx.doi.org/10.1016/j.critrevonc.2024.104597</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_98291ebd2e8bd1ca0ffa529525473f33 |
| identifier_str_mv | 10.1016/j.critrevonc.2024.104597 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30173485 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysisJaber H. Jaradat (21632849)Ibraheem M. Alkhawaldeh (17430888)Yousef Al-Bojoq (22282816)Monther N. Ramadan (22282819)Mohammad T. Abuawwad (17632242)Yasmeen Jamal Alabdallat (19920491)Abdulqadir J. Nashwan (11659453)Biomedical and clinical sciencesCardiovascular medicine and haematologyImmunologyOncology and carcinogenesisPharmacology and pharmaceutical sciencesIbrutinibBTKBruton tyrosine kinase inhibitorCNSLCentral nervous system lymphomaLymphoma<h3>Background</h3><p dir="ltr"><u>Primary central nervous system lymphoma</u> (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose <u>methotrexate</u> (HD-MTX), are effective treatments, the relapse rates remain high, prompting the exploration of novel therapeutic options.<u> Ibrutinib</u>, an irreversible <u>Bruton tyrosine kinase</u> (BTK) inhibitor, has shown promise in various B-cell <u>malignancies</u>, including <u>CNSL.</u></p><h3>Objectives</h3><p dir="ltr">This <u>systematic review </u>and meta-analysis aimed to evaluate the safety and efficacy of ibrutinib in the treatment of CNSL, focusing on <u>overall response</u> (OR), complete response (CR), partial response (PR), progression-free survival (PFS), overall survival (OS), and <u>adverse events.</u></p><h3>Methods</h3><p dir="ltr">A comprehensive search of the <u>PubMed</u>, Google Scholar, and <u>Scopus</u> databases was conducted. The included studies were prospective and retrospective studies focusing on ibrutinib as <u>monotherapy</u> or in combination with CNSL. <u>Data extraction</u> and quality assessment were independently performed by two reviewers, and statistical analyses were conducted using R version 4.4.0.</p><h3>Results</h3><p dir="ltr">Fourteen studies (eight <u>cohort studies </u>and six clinical trials) involving 784 patients were included. The median age was 61 years, with nearly equal sex distribution. The meta-analysis for CNSL, the partial response rate was 29.52 %, complete response rate was 49.19 %, and overall response rate was 72.11 %. For PCNSL, the partial response rate was 20.85 %, complete response rate was 48.13 %, and overall response rate was 66.92 %. For SCNSL, the partial response rate was 29.42 %, complete response rate was 44.64 %, and overall response rate was 66.82 %. Significant heterogeneity was observed in some comparisons. There were no significant differences in the efficacy of ibrutinib between CNSL subtypes.</p><h3>Conclusions</h3><p dir="ltr"><u>Ibrutinib</u> shows promising efficacy in improving partial and complete response rates in CNSL. The substantial heterogeneity observed underscores the need for further well-designed studies to confirm these findings and explore the optimal use of ibrutinib in CNSL treatment protocols. Future trials should consider comparing ibrutinib to standard therapies and investigate its long-term efficacy and safety profile.</p><h2>Other Information</h2><p dir="ltr">Published in: Critical Reviews in Oncology/Hematology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.critrevonc.2024.104597" target="_blank">https://dx.doi.org/10.1016/j.critrevonc.2024.104597</a></p>2024-12-24T18:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.critrevonc.2024.104597https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_ibrutinib_in_central_nervous_system_lymphoma_A_systematic_review_and_meta-analysis/30173485CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/301734852024-12-24T18:00:00Z |
| spellingShingle | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis Jaber H. Jaradat (21632849) Biomedical and clinical sciences Cardiovascular medicine and haematology Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Ibrutinib BTK Bruton tyrosine kinase inhibitor CNSL Central nervous system lymphoma Lymphoma |
| status_str | publishedVersion |
| title | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis |
| title_full | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis |
| title_short | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis |
| title_sort | Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Ibrutinib BTK Bruton tyrosine kinase inhibitor CNSL Central nervous system lymphoma Lymphoma |